<bill session="114" type="h" number="6284" updated="2018-11-21T21:23:53Z">
  <state datetime="2016-09-28">REFERRED</state>
  <status>
    <introduced datetime="2016-09-28"/>
  </status>
  <introduced datetime="2016-09-28"/>
  <titles>
    <title type="short" as="introduced">Eliminate Price Increases Act of 2016</title>
    <title type="short" as="introduced">EPI Act</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.</title>
    <title type="display">EPI Act</title>
  </titles>
  <sponsor bioguide_id="S000510"/>
  <cosponsors/>
  <actions>
    <action datetime="2016-09-28">
      <text>Introduced in House</text>
    </action>
    <action datetime="2016-09-28" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2016-09-28T04:00:00Z" status="Introduced in House">Eliminate Price Increases Act of 2016 or the EPI Act

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the manufacturer of a brand name drug from authorizing or commencing the manufacturing, marketing, selling, or distributing of a generic version of the drug from the time the manufacturer is notified by a generic manufacturer that a generic drug application has been submitted until the expiration or forfeiture of the 180-day exclusivity period granted to the generic manufacturer.</summary>
  <committee-reports/>
</bill>
